Contrary to CTCs, which use, for example, EpCAM as the enrichment antigen, the number of non-diseased cells selected by antibodies targeting leukemic associated and multiple myeloma antigens is high because non-diseased cells can also express the enrichment antigen (i.e., CD19, CD34, CD117, CD33, or CD138). The gene discussed is CD34; the disease is plasma cell myeloma.